NCT00005757|Completed
Loading search results
Sponsor study identifier
Secondary identifiers
NIH
observational
293
0 countries
N/A
Study Start
September 1997
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2001
Actual (reported)Study Completion
August 2001
Actual (reported)To determine whether differences in the activity of the renin-angiotensin and bradykinin systems are involved in the pathogenesis of blood pressure variation in African Americans.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2001
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 1997
Date type not reportedThis date has not been verified as actual or estimated.
May 25, 2000
Actual (reported)May 26, 2000
Actual (reported)August 2001
Actual (reported)August 2001
Actual (reported)Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension. 1998 Dec;32(6):965-71. doi: 10.1161/01.hyp.32.6.965.
Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998 Oct 29;339(18):1285-92. doi: 10.1056/NEJM199810293391804.
Nancy Brown
Vanderbilt University
293 participants (actual enrollment reported by the registry).
First Submitted
May 25, 2000
First Posted
May 26, 2000
Study Start
September 1997
Date type not reportedThis date has not been verified as actual or estimated.
Murphey LJ, Hachey DL, Vaughan DE, Brown NJ, Morrow JD. Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay. Anal Biochem. 2001 May 1;292(1):87-93. doi: 10.1006/abio.2001.5073.
Gainer JV, Brown NJ, Bachvarova M, Bastien L, Maltais I, Marceau F, Bachvarov DR. Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. Am J Hypertens. 2000 Dec;13(12):1268-73. doi: 10.1016/s0895-7061(00)01215-2.
Murphey LJ, Kumar S, Brown NJ. Endogenous bradykinin and the renin and pressor responses to furosemide in humans. J Pharmacol Exp Ther. 2000 Nov;295(2):644-8.
Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000 Sep;58(3):1219-27. doi: 10.1046/j.1523-1755.2000.00277.x.
Murphey LJ, Gainer JV, Vaughan DE, Brown NJ. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation. 2000 Aug 22;102(8):829-32. doi: 10.1161/01.cir.102.8.829.
Murphey LJ, Hachey DL, Oates JA, Morrow JD, Brown NJ. Metabolism of bradykinin In vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. J Pharmacol Exp Ther. 2000 Jul;294(1):263-9.
Wilsdorf T, Gainer JV, Murphey LJ, Vaughan DE, Brown NJ. Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm. Hypertension. 2001 Apr;37(4):1136-40. doi: 10.1161/01.hyp.37.4.1136.
Primary Completion
August 2001
Actual (reported)Study Completion
August 2001
Actual (reported)Last Updated
November 28, 2016
Record last verified: 2016-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: